CD274 and Cachexia: Knowing that a move forward on the defined path of cachexia, a weight loss of more than 5% in the previous 6 months, or a weight loss of more than 2% in patients with a BMI of less than 20 Kg/m2, Jo et al. investigated the predictive value of cachexia in advanced NSCLC patients (133 patients) treated with PD-L1 inhibitors (pembrolizumab); they looked at the levels of pro-inflammatory cytokines and appetite-related hormones in the blood serum, which are linked to the pathogenesis of cancer cachexia.